EMA reflection paper on Patient Experience Data (PED)

1:1
First published on 29 September, this EMA reflection paper encourages early dialogue with regulators on how patient experience data can strengthen evidence packages in medicines development and marketing authorisation.

This EMA reflection paper promotes the inclusion of patient experience data (PED) in medicine development programmes and marketing authorisation applications, defining PED as data that directly reflect the patient experience without interpretation by clinicians or others. It encourages early engagement with regulators to discuss planned approaches and highlights relevant PED types and sources, including patient‑reported outcomes, patient preference studies, patient‑generated digital data, clinical trial data and real‑world data, with the aim of improving how patient experience is captured and used in regulatory decision‑making.

Acces this publication (pdf)
scientific paper

Source

European Medicines Agency (EMA)

Link to cite

Acces to Link >

You might also be interested in

Radka Kaneva and Petia Stratieva, Sofia, March 2026

“National Mirror Groups are essentially a bridge — bringing European developments, standards and opportunities to clinicians and researchers.”

ERDERA interviews Prof. Radka Kaneva and Dr Petia Stratieva, two leading members of Bulgaria’s National Mirror Group (NMG), to explore how the country is working to align its rare disease ecosystem with European developments.
Gdańsk - Medical University of Gdańsk

From Hyderabad to Gdansk: collaborative diagnostic efforts that bridge research and clinical practice to shorten patients’ path to answers

ERDERA joins the Wilhelm Foundation and the Gdansk Medical University and Clinical Centre to strengthen phenotype‑led diagnosis for people living with undiagnosed conditions
European Parliament

European Parliament draft report urges a binding EU rare disease action framework

A legislative own initiative file in the Parliament’s new public health committee sets out what an EU “rare disease action framework” could look like — and why it could change how Europe measures progress for patients.
Woman helping out a person with a disease

Women’s Day highlights widening gender inequalities in rare diseases

Drawing on Europe-wide patient and carer surveys, ERDERA highlights how gender can shape diagnostic delays, care burden and the evidence base for rare-disease research.

ERDERA's

search form